News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
688,050 Results
Type
Article (40154)
Company Profile (285)
Press Release (647611)
Section
Business (205849)
Career Advice (1983)
Deals (35670)
Drug Delivery (81)
Drug Development (82030)
Employer Resources (167)
FDA (16203)
Job Trends (14937)
News (347882)
Policy (32680)
Tag
Academia (2569)
Africa (721)
Alliances (49801)
Alzheimer's disease (1165)
Approvals (16131)
Arizona (178)
Artificial intelligence (88)
Asia (37605)
Australia (6129)
Bankruptcy (352)
Best Places to Work (11482)
Biosimilars (66)
Biotechnology (205)
Breast cancer (77)
C2C Services and Suppliers (79479)
California (2149)
Canada (1016)
Cancer (660)
Career advice (1653)
Cell therapy (158)
China (169)
Clinical research (64504)
Collaboration (199)
Colorado (87)
Compensation (113)
Connecticut (90)
COVID-19 (2511)
Cystic fibrosis (78)
Data (475)
Diabetes (98)
Diagnostics (6085)
Drug pricing (72)
Earnings (84245)
Employer resources (142)
Europe (81436)
Events (109920)
Executive appointments (186)
FDA (16512)
Florida (309)
Funding (191)
Gene therapy (105)
Georgia (69)
GLP-1 (535)
Government (4335)
Healthcare (18857)
Hotbed/Location (484356)
Illinois (279)
Indiana (155)
Infectious disease (2552)
Inflammatory bowel disease (95)
Interviews (306)
IPO (16346)
Job creations (3647)
Job search strategy (1417)
Kansas (95)
Layoffs (413)
Legal (7865)
Lung cancer (135)
Manufacturing (113)
Maryland (445)
Massachusetts (1777)
Medical device (13124)
Medtech (13129)
Mergers & acquisitions (19243)
Metabolic disorders (289)
Michigan (132)
Minnesota (229)
Neuroscience (1349)
New Jersey (654)
New York (668)
NextGen Class of 2024 (6548)
Non-profit (4492)
North Carolina (618)
Northern California (929)
Obesity (176)
Ohio (115)
Opinion (178)
Patents (80)
Pennsylvania (632)
People (56625)
Phase I (20048)
Phase II (28380)
Phase III (21241)
Pipeline (143)
Postmarket research (2581)
Preclinical (8467)
Radiopharmaceuticals (241)
Rare diseases (151)
Real estate (5944)
Regulatory (21513)
Research institute (2356)
Resumes & cover letters (347)
South America (1102)
Southern California (864)
Startups (3625)
Texas (276)
United States (9577)
Vaccines (502)
Washington State (267)
Weight loss (142)
Date
Last 7 days (661)
Last 30 days (2551)
Last 365 days (37017)
2024 (27861)
2023 (40496)
2022 (51695)
2021 (56236)
2020 (54543)
2019 (47059)
2018 (35458)
2017 (32658)
2016 (32028)
2015 (38064)
2014 (31749)
2013 (26720)
2012 (28926)
2011 (29660)
2010 (27609)
688,050 Results for "citius oncology inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc.
August 13, 2024
·
9 min read
Press Releases
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology
September 5, 2024
·
14 min read
Press Releases
Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc.
August 5, 2024
·
8 min read
Business
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update
Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal second quarter 2024 ended March 31, 2024.
May 14, 2024
·
13 min read
Approvals
Citius Scores FDA Approval in Cutaneous T Cell Lymphoma
Citius Pharmaceuticals’ Lymphir is a reformulated version of denileukin diftitox—an FDA-approved cancer therapy—and the only treatment for cutaneous T cell lymphoma that targets the IL-2 receptor located on malignant T cells and Tregs.
August 9, 2024
·
2 min read
·
Tristan Manalac
Deals
Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc.
Citius Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement, dated October 23, 2023, for a proposed merger of TenX and Citius Pharma’s wholly owned oncology subsidiary that will continue as a public company listed on the Nasdaq exchange.
October 24, 2023
·
18 min read
Pharm Country
Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor Conferences
Citius Pharmaceuticals, Inc. today announced its participation in two upcoming investor conferences.
May 10, 2024
·
2 min read
Pharm Country
Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program
Citius Pharmaceuticals, Inc. today announced that the Company has received $2.4 million in non-dilutive capital.
March 7, 2024
·
5 min read
Business
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update
August 12, 2024
·
13 min read
Business
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2023 Financial Results and Provides Business Update
Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal full year ended September 30, 2023.
January 2, 2024
·
13 min read
1 of 68,805
Next
